Tanikawa, Japan, 2022, hopeful preclinical work on degradation of Spike with nattokinase which is derived from Bacillus subtilis var natto. A proteolytic enzyme works as thrombolytic and in catabolism of several proteins. Should be advanced in trials of Spike syndromes. pic.twitter.com/zCdINGYzpa
— Peter A. McCullough, MD, MPH® (@P_McCulloughMD) October 2, 2022
